Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

(2019) Josef Coresh et al.   Lancet Diabetes & Endocrinology

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy

(2018) Misghina Weldegiorgis et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

(2017) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis

(2016) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy

(2015) A. Thompson et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

GFR Decline as an End Point in Trials of CKD: A Viewpoint From the FDA

(2014) Aliza Thompson et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease

(2014) Robert W. Schrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Cohort Profile: The Chronic Kidney Disease Prognosis Consortium

(2012) K. Matsushita et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE